Abstract

Silicosis is a diffuse interstitial lung disease caused by sustained inhalation of silica and silicates. Several cytokines are activated by their inhalation and can mediate the process of pulmonary fibrosis. The identification of biomarkers could allow an early diagnosis before the development of radiological alterations and help monitor the evolution of patients. The objetive of this study was to determine the clinical significance of specific biomarkers, to estimate their association with the development, severity and/or progression of silicosis, and identify determinants of this evolution. We conducted a prospective observational study in patients attending the pulmonology clinic from 2009 to 2018. Serum levels of the following inflammatory mediators were assessed: interleukin-6 (IL-6), interleukin 2 receptor subunit alpha (IL2R) interleukin 1 beta (IL1B), interleukin-8 (IL-8), tumour necrosis factor-alpha (TNF-α), transforming growth factor-beta1 (TGF-β1), alpha-1 antitrypsin (AAT), C-reactive protein (CRP), lactate dehydrogenase (LDH) and ferritin in subjects exposed to silica, with and without silicosis. Association between those inflammatory mediators with lung function measurements and radiological severity of disease and their impact on prognosis were analysed. 337 exposed to silica (278 with silicosis) and 30 subjects in the control group were included. IL-8, α1AT, ferritin, CRP and LDH levels were higher in silicosis than in those exposed to silica without silicosis. IL-8, LDH and AAT levels were associated with progression of silicosis and IL-6, IL-8, LDH, AAT, ferritin, and CRP with vital status. The results of the ROC analysis indicated the potential of IL-8 as a biomarker in the presence of silicosis and for the prediction of mortality.

Details

Title
Serum levels of inflammatory mediators as prognostic biomarker in silica exposed workers
Author
Blanco-Pérez, José Jesús 1 ; Blanco-Dorado, Sara 2 ; Rodríguez-García, Javier 3 ; Gonzalez-Bello, Mª Elena 4 ; Salgado-Barreira Ángel 5 ; Caldera-Díaz, Adriana Carolina 6 ; Pallarés-Sanmartín Abel 4 ; Fernandez-Villar, Alberto 4 ; González-Barcala, Francisco Javier 7 

 University Hospital Complex of Vigo, Department of Pneumonology, Pontevedra, Spain (GRID:grid.411855.c) (ISNI:0000 0004 1757 0405); IRIDIS Group (Investigation in Rheumatology and Immuno-Mediated Diseases) Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain (GRID:grid.411855.c) 
 University Hospital Complex of Santiago de Compostela, Department of Pharmacy, Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945) 
 University Hospital Complex of Santiago de Compostela (CHUS)-SERGAS, Department of Clinical Analysis, Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897) 
 University Hospital Complex of Vigo, Department of Pneumonology, Pontevedra, Spain (GRID:grid.411855.c) (ISNI:0000 0004 1757 0405) 
 Galicia Sur Health Research Institute (IIS Galicia Sur), Methodology and Statistics Unit, Vigo, Spain (GRID:grid.411855.c) 
 University Hospital Complex of Vigo, Department of Radiology, Pontevedra, Spain (GRID:grid.411855.c) (ISNI:0000 0004 1757 0405) 
 University Hospital Complex of Santiago de Compostela, Spanish Biomedical Research Networking Centre-CIBERES, Department of Pneumonology, Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2544996962
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.